Deltex grows production capacity:
This article was originally published in Clinica
UK haemodynamic monitoring company Deltex Medical is to raise around £1.9m ($3.8m) through the sale of over eight million new shares. The firm said it will use the proceeds to significantly expand its manufacturing capability in response to the sales growth following the start of US reimbursement coverage of its CardioQ haemodynamic monitoring system at the end of May. Deltex plans to more than double its existing production capacity, automate certain processes in the manufacture of its disposable probes, further improve the functionality of its CardioQ monitor, and continue to broaden its IP position.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.